Athanor Capital, LP Sage Therapeutics, Inc. Transaction History

Athanor Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $218,093 - $315,098	-3,974 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $57,085 - $78,182	-808 Reduced 16.9%	3,974 $297,000
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $279,316 - $425,884	4,782 New	4,782 $414,000
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $154,319 - $208,956	-1,100 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$157.85 - $183.09 $173,635 - $201,399	1,100 New	1,100 $201,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $284M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.